Ka Kit Wong, MBBS

Dr. Wong is a nuclear medicine physician working as faculty at the University of Michigan since 2010. His academic interests include endocrine, pediatric, and oncologic nuclear medicine, hybrid PET-CT and SPECT-CT imaging and PET imaging with non-FDG radiotracers. He is originally from Australia and graduated in 1998 from University of Sydney for his medical degree, and did residency in Internal Medicine then Nuclear Medicine, and completed a Nuclear Medicine Fellowship at University of Michigan (UM), between 2006-2008.

He is presently the Director of Therapy Ambulatory Care Unit (ACU), and recently started the role of Program Director of the Nuclear Medicine Residency Program. He leads the peptide receptor radionuclide therapy (PRRT) / radioligand therapy (RLT) programs at UM. Dr. Wong has been involved with Nuclear Medicine Therapy since 2010 and with the introduction of these new cancer treatments, and has an interest in Dosimetry applications to provide patient-centric care. The Therapy Clinic annually performs 150-200 Lu177-DOTATATE therapies, up 130-150 radioiodine therapies, 40+ Ra-223 therapies, Lu177-PSMA, bone palliative radionuclides, with a nationally recognized dosimetry program.

He is also the faculty lead for Nuclear Medicine for C.S. Mott Children's hospital Radiology Pediatric Service since 2016, supporting Pediatric Nuclear Medicine education and Ped TB and Uroradiology meetings. He is a member of the Pediatric Nuclear Medicine Council, SNMMI. He has experience in the role of Hybrid Molecular Imaging (SPECT/CT and PET/CT) in thyroid disorders, imaging and radionuclide treatment of pediatric thyroid disorders. He has been involved with radioiodine (RAI) therapies of thyroid cancer and hyperthyroidism since 2010, for both adult and pediatric patients.

He assumed the position of Program Director of ACGME Nuclear Medicine Residency training since July 2022; this accredited program aims to train doctors for ABNM board eligibility and prepare them for independent diagnostic and therapeutic nuclear medicine practice. The program has 3 nationally designated training spots, and accepts applicants from Radiology and Internal Medicine backgrounds, via traditional, parallel and alternative pathways. The program has 8 core Medical Faculty, physicists and radiochemist on Faculty, and provide a comprehensive 1-3 year training program, for interpretation of General nuclear medicine scans, PET scans, Therapy Clinic experience to achieve NRC 390 authorized user status, and opportunity for presenting at tumors boards, teaching and clinical research.